- Home
- ASYS vs PRLD Comparison
ASYS vs PRLD Comparison
Compare ASYS & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASYS
- PRLD
- Stock Information
- Founded
- ASYS 1981
- PRLD 2016
- Country
- ASYS United States
- PRLD United States
- Employees
- ASYS N/A
- PRLD N/A
- Industry
- ASYS Industrial Machinery/Components
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- ASYS Technology
- PRLD Health Care
- Exchange
- ASYS Nasdaq
- PRLD Nasdaq
- Market Cap
- ASYS 83.0M
- PRLD 69.1M
- IPO Year
- ASYS N/A
- PRLD 2020
- Fundamental
- Price
- ASYS $7.20
- PRLD $1.76
- Analyst Decision
- ASYS
- PRLD Strong Buy
- Analyst Count
- ASYS 0
- PRLD 3
- Target Price
- ASYS N/A
- PRLD $4.00
- AVG Volume (30 Days)
- ASYS 249.3K
- PRLD 3.1M
- Earning Date
- ASYS 12-08-2025
- PRLD 10-31-2025
- Dividend Yield
- ASYS N/A
- PRLD N/A
- EPS Growth
- ASYS N/A
- PRLD N/A
- EPS
- ASYS N/A
- PRLD N/A
- Revenue
- ASYS $83,634,000.00
- PRLD $7,000,000.00
- Revenue This Year
- ASYS N/A
- PRLD N/A
- Revenue Next Year
- ASYS $12.93
- PRLD N/A
- P/E Ratio
- ASYS N/A
- PRLD N/A
- Revenue Growth
- ASYS N/A
- PRLD N/A
- 52 Week Low
- ASYS $3.20
- PRLD $0.61
- 52 Week High
- ASYS $10.80
- PRLD $4.22
- Technical
- Relative Strength Index (RSI)
- ASYS 39.43
- PRLD 51.40
- Support Level
- ASYS $7.80
- PRLD $1.43
- Resistance Level
- ASYS $8.46
- PRLD $4.19
- Average True Range (ATR)
- ASYS 0.45
- PRLD 0.39
- MACD
- ASYS -0.09
- PRLD 0.10
- Stochastic Oscillator
- ASYS 3.38
- PRLD 19.80
About ASYS Amtech Systems Inc.
Amtech Systems Inc is a manufacturer of capital equipment, including thermal processing and wafer polishing, and related consumables used in fabricating semiconductor devices, such as silicon carbide (SiC) and silicon power chips, electronic assemblies, and light-emitting diodes (LEDs). the company has two segments; based on the industries served: Thermal Processing Solutions (formerly called Semiconductor) and Semiconductor Fabrication Solutions (formerly called Material and Substrate). Maximum revenue is generated from Thermal Processing Solutions. Maximum revenue is from Asia Region.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.